Short Interest in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Rises By 33.0%

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) saw a significant growth in short interest in December. As of December 31st, there was short interest totaling 10,334,707 shares, a growth of 33.0% from the December 15th total of 7,772,345 shares. Approximately 5.3% of the company’s stock are short sold. Based on an average daily volume of 1,680,832 shares, the short-interest ratio is currently 6.1 days. Based on an average daily volume of 1,680,832 shares, the short-interest ratio is currently 6.1 days. Approximately 5.3% of the company’s stock are short sold.

Zimmer Biomet Stock Down 1.5%

Shares of NYSE ZBH traded down $1.33 during trading hours on Friday, hitting $87.42. The stock had a trading volume of 2,681,302 shares, compared to its average volume of 1,825,838. The firm’s 50-day moving average price is $91.59 and its two-hundred day moving average price is $96.50. Zimmer Biomet has a 52 week low of $85.33 and a 52 week high of $114.44. The company has a market capitalization of $17.32 billion, a P/E ratio of 21.64, a P/E/G ratio of 2.23 and a beta of 0.62. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.39 and a current ratio of 2.43.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $2.01 billion. During the same period in the previous year, the company earned $1.74 earnings per share. The company’s revenue was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Analysts anticipate that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio is presently 23.76%.

Institutional Trading of Zimmer Biomet

A number of institutional investors and hedge funds have recently made changes to their positions in ZBH. Resona Asset Management Co. Ltd. increased its holdings in shares of Zimmer Biomet by 5.7% during the second quarter. Resona Asset Management Co. Ltd. now owns 67,915 shares of the medical equipment provider’s stock worth $6,197,000 after buying an additional 3,634 shares in the last quarter. SG Americas Securities LLC grew its position in Zimmer Biomet by 29.2% during the 3rd quarter. SG Americas Securities LLC now owns 61,110 shares of the medical equipment provider’s stock worth $6,019,000 after acquiring an additional 13,812 shares during the last quarter. QSM Asset Management Ltd grew its position in Zimmer Biomet by 36.1% during the 2nd quarter. QSM Asset Management Ltd now owns 111,500 shares of the medical equipment provider’s stock worth $10,174,000 after acquiring an additional 29,600 shares during the last quarter. Truist Financial Corp increased its holdings in Zimmer Biomet by 34.4% during the 2nd quarter. Truist Financial Corp now owns 26,819 shares of the medical equipment provider’s stock valued at $2,446,000 after purchasing an additional 6,867 shares in the last quarter. Finally, Magellan Asset Management Ltd raised its position in Zimmer Biomet by 16.8% in the 2nd quarter. Magellan Asset Management Ltd now owns 505,901 shares of the medical equipment provider’s stock valued at $46,143,000 after purchasing an additional 72,613 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on ZBH. Barclays dropped their price target on Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating on the stock in a research report on Wednesday, November 5th. The Goldman Sachs Group cut Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 target price on the stock. in a research note on Friday, January 9th. Wall Street Zen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday. Evercore ISI upgraded shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and raised their price target for the stock from $94.00 to $120.00 in a report on Monday, January 5th. Finally, UBS Group dropped their price objective on shares of Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating on the stock in a research note on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $107.33.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.